Gene expression profiling by transcriptome analysis identified somatic inactivating mutations of the tumor suppressor gene TP53 and activating mutations of the proto-oncogene β-catenin (CTNNB1) as frequent mutations in ACC, which seemed to be mutually exclusive and were observed only in the poor-outcome ACC group [43]. The gene discussed is TP53; the disease is adrenal cortex carcinoma.